Fundamental change seems increasingly inevitable, but at the same time increasingly unimaginable. A variety of public private partnering arrangements and innovative financing mechanisms has begun to change the neglected disease landscape over the last decade. How significant are these public-private partnership (PPP) arrangements? Are these players likely to endure? Do they deserve the continue...

489 Vol. 7, No. 3, May–June 2001 Emerging Infectious Diseases of serious gram-positive infections in humans (with no animal use counterparts) are in the pharmaceutical pipeline (e.g., LY333328 and daptomycin) or have recently been approved (e.g., linezolid). We hope that a fair balance can be achieved by the human medical and the animal health and production communities with regard to the types...

In 2018, the Central Bureau of Statistics noted that pharmaceutical industry grew 7.36 percent and slowed by 5.59 during Covid-19 pandemic in 2020. Fluctuations growth sector before encouraged increased competition concentration. This study examines concentration businesses listed on Indonesia Stock Exchange from first quarter 2018 to third The method used this is a quantitative approach with r...

Note: The information regarding the pharmaceutical sector and the company are accurate as collected from various cited sources. The problem contains all the characteristics of the underlying problem faced by Pfizer. It has been simplified for the purpose of keeping the model size manageable as a case study and the data has been altered for reasons of confidentiality. The authors created the cas...

Inhalation product development is an important area of activity for the pharmaceutical sector. Asthma and chronic obstructive pulmonary disease (COPD) are becoming increasingly common and there is growing recognition of the benefits of the pulmonary route for systemic drug delivery. The industry is responding by investing heavily in both formulation and device research. Inhalation delivery plat...

Rajesh Gandhi, PhD, is a senior research scientist in Ranbaxy Research Laboratories (Gurgaon, India), Yasvanth Ashokraj is a doctoral student, Chaman Lal Kaul, PhD, is the director of the National Institute of Pharmaceutical Education and Research (NIPER), and Ramesh Panchagnula, PhD, is a professor and head of the Department of Pharmaceutics, NIPER, Sector 67, S.A.S. Nagar (Punjab) 160062 Indi...